
Please try another search
(Reuters) - The world's first medical trial authorised to deliberately expose participants to the coronavirus is seeking more volunteers as it steps up efforts to help develop better vaccines.
The Oxford University trial was launched last April, three months after Britain became the first country to approve what are known as challenge trials for humans involving COVID-19.
Its first phase, still ongoing, has focused on finding out how much of the virus is needed to trigger an infection while the second will aim to determine the immune response needed to ward one off, the university said in a statement on Tuesday.
Researchers are close to establishing the weakest possible virus infection that assures about half of people exposed to it get asymptomatic or mild COVID-19.
They then plan to expose volunteers - all previously naturally infected or vaccinated - to that dose of the virus's original variant to determine what levels of antibodies or immune T-cells are required to prevent an infection.
"This is the immune response we then need to induce with a new vaccine," said Helen McShane, Oxford University Professor of Vaccinology and the study's chief investigator.
The trial's findings will help make future vaccine development much quicker and more efficient, the statement said.
Global immunologists have been seeking to pinpoint the immune reaction that a vaccine must produce to shield against the illness, known as a correlate of protection. Once discovered, the need for mass vaccine trials is greatly reduced.
Scientists have used human challenge trials for decades to develop treatments against many infectious diseases, but this is the first known such research into COVID-19.
A drawback is the risk of harm to volunteers contracting the disease but the university is taking precautions.
Participants will need to be healthy and aged 18-30. They will be quarantined for at least 17 days and any who develop symptoms will be given Regeneron (NASDAQ:REGN)'s monoclonal antibody treatment Ronapreve.
(Reuters) - Chicago police arrested a suspect in a fatal shooting that escalated from a fight outside a fast food restaurant and spilled on to a nearby train line, authorities and...
WASHINGTON (Reuters) - Former New York City Mayor Bill De Blasio said on Friday he would make a run for Congress in the newly created 10th district of New York, which includes...
(Bloomberg) -- Shanghai found the first cases of Covid-19 outside of quarantine in six days, raising questions about whether the easing of the city’s lockdown will be...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.